Flecainide and disopyramide significantly increased ST20 and QRS duration in Brugada patients, with a 0.15 mV ST20 increase with flecainide separating Brugada from control patients without overlap.
Case-Control (n=22)
Do sodium channel blockers amplify ECG abnormalities such as ST segment elevation and QRS prolongation in patients with Brugada syndrome compared to controls?
Sodium channel blockers, particularly flecainide, amplify ST segment elevation and QRS prolongation in Brugada syndrome, which can be utilized to unmask the syndrome.
INTRODUCTION: Brugada syndrome is characterized by an ST segment elevation in leads V1-V3 and a high incidence of ventricular fibrillation (VF). A mutation in a cardiac Na+ channel gene, SCN5A, has been linked to Brugada syndrome, and sodium channel blockers have been shown to be effective in unmasking the syndrome when concealed. The aim of this study was to examine the effects of Na+ channel blockers on ST segment elevation, QRS, corrected QT (QTc) interval, and ventricular arrhythmias in patients with Brugada syndrome. METHODS AND RESULTS: We examined the effects of three different Na+ channel blockers (flecainide, disopyramide, and mexiletine) on the amplitude of the ST segment 20 msec after the end of QRS (ST20), QRS duration, QTc interval measured from 12-lead ECG, and ventricular arrhythmias in 12 Brugada and 10 control patients. Maximum ST20 observed in the V2 or V3 leads under baseline conditions was greater in the Brugada patients than in control patients, whereas QRS duration and maximum QTc interval were no different between the two groups. Flecainide and disopyramide, but not mexiletine, significantly increased maximum ST20 and QRS duration in both groups, although these effects were much more pronounced in the Brugada patients. The increases in ST20 and QRS duration with flecainide were significantly larger than those with disopyramide. An increase of 0.15 mV in ST20 with flecainide separated the two groups without overlap. Ventricular premature complexes developed only with flecainide in Brugada patients (3/12) displaying a marked ST elevation but not widening of QRS. CONCLUSION: Our findings suggest that Na+ channel blockers amplify existing I(Na) and possibly other ion channel defects, with a potency inversely proportional to the rate of dissociation of the drug from the Na+ channel, thus causing a prominent elevation of the ST segment and, in some cases, prolongation of QRS duration in patients with Brugada syndrome.
Shimizu et al. (2000) conducted a case-control in Brugada syndrome (n=22). Sodium channel blockers (flecainide, disopyramide, and mexiletine) vs. Control patients was evaluated on Amplitude of the ST segment 20 msec after the end of QRS (ST20), QRS duration, QTc interval, and ventricular arrhythmias. Flecainide and disopyramide significantly increased ST20 and QRS duration in Brugada patients, with a 0.15 mV ST20 increase with flecainide separating Brugada from control patients without overlap.